PSNL vs. BDSX, BNR, ENZ, RNLX, XGN, PMD, DMTK, BGLC, OPGN, and FRES
Should you be buying Personalis stock or one of its competitors? The main competitors of Personalis include Biodesix (BDSX), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), Renalytix (RNLX), Exagen (XGN), Psychemedics (PMD), DermTech (DMTK), BioNexus Gene Lab (BGLC), OpGen (OPGN), and Fresh2 Group (FRES). These companies are all part of the "medical laboratories" industry.
Personalis (NASDAQ:PSNL) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.
61.9% of Personalis shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 4.1% of Personalis shares are held by insiders. Comparatively, 69.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Personalis has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Biodesix has a net margin of -85.80% compared to Personalis' net margin of -124.89%. Personalis' return on equity of -58.31% beat Biodesix's return on equity.
Biodesix has lower revenue, but higher earnings than Personalis. Biodesix is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.
Personalis currently has a consensus target price of $5.00, suggesting a potential upside of 284.62%. Biodesix has a consensus target price of $3.10, suggesting a potential upside of 116.78%. Given Personalis' higher probable upside, analysts plainly believe Personalis is more favorable than Biodesix.
Personalis received 83 more outperform votes than Biodesix when rated by MarketBeat users. However, 72.97% of users gave Biodesix an outperform vote while only 65.48% of users gave Personalis an outperform vote.
In the previous week, Personalis and Personalis both had 2 articles in the media. Biodesix's average media sentiment score of 0.93 beat Personalis' score of 0.91 indicating that Biodesix is being referred to more favorably in the news media.
Summary
Personalis and Biodesix tied by winning 8 of the 16 factors compared between the two stocks.
Get Personalis News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Personalis Competitors List
Related Companies and Tools
